<DOC>
	<DOCNO>NCT02268812</DOCNO>
	<brief_summary>This open-label , long-term , multi-centre multi-national postmarketing observational registry . The objective study monitor long-term efficacy , safety , tolerability quality life outcomes associate Prialt analgesic utilise intrathecal management severe chronic pain .</brief_summary>
	<brief_title>Patient Registry Intrathecal Pain Management Europe Prialt ( Ziconotide Intrathecal Infusion ) Alternative Drugs Management Severe , Chronic Pain .</brief_title>
	<detailed_description>This obsevational non-interventional registry . All patient sign date Informed Consent Form ( ICF ) enrolment ( Baseline Visit ) . Normal clinical practice follow . Patients continue follow usual schedule clinic visit determine physician , information patient-completed questionnaire collect ( schedule interval time coincide pump refill ) . The post-baseline assessment schedule expect 6 week , 4 month , every 4 month thereafter .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Ziconotide</mesh_term>
	<criteria>Inclusion Criteria Patients eligible enrol onto registry give informed consent andmeet follow criterion : Patient 's physician deem initiation/switch intrathecal analgesia appropriate , patient presently utilising Prialt Patient diagnosis severe , chronic pain intrathecal infusion indicate Patient least 18 year age time study entry All patient start Prialt comply indication warn current approve version Summary Product Characteristics ( SmPC ) . Exclusion Criteria Patients meet follow criterion eligible enrol registry : Patient pregnant lactate female Patient receive intrathecal chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Pain Management</keyword>
	<keyword>Europe</keyword>
	<keyword>Intrathecal</keyword>
</DOC>